The DOI matches its Crossref record.
Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine
Abstract
Objective.—To evaluate the efficacy and tolerability of treatment with a combination of sumatriptan 50 mg (encapsulated) and naproxen sodium 500 mg administered concurrently in the acute treatment of migraine. Background.—The pathogenesis of migraine involves multiple peripheral and central neural mechanisms that individually have been successful targets for acute (abortive) and preventive treatment. This suggests that multimechanism therapy, which acts on multiple target sites, may confer improved efficacy and symptom relief for patients with migraine. Design and Methods.—This was a multicenter, randomized, double‐blind, double‐dummy, placebo‐controlled, four‐arm study. Participants (n = 972) treated a single moderate or severe migraine attack with placebo, naproxen sodium 500 mg, sumatriptan 50 mg, or a combination of sumatriptan 50 mg and naproxen sodium 500 mg. In the latter two treatment arms, the sumatriptan tablets were encapsulated in order to achieve blinding of the study. Results.—In the sumatriptan plus naproxen sodium group, 46% of subjects achieved 24‐hour pain relief response (primary endpoint), which was significantly more effective than sumatriptan alone (29%), naproxen sodium alone (25%), or placebo (17%) ( P < .001). Two‐hour headache response also significantly favored the sumatriptan 50 mg plus naproxen sodium 500 mg therapy (65%) versus sumatriptan (49%), naproxen sodium (46%), or placebo (27%) ( P < .001). A similar pattern of between‐group differences was observed for 2‐hour pain‐free response and sustained pain‐free response ( P < .001). The incidence of headache recurrence up to 24 hours after treatment was lowest in the sumatriptan plus naproxen sodium group (29%) versus sumatriptan alone (41%; P = .048), versus naproxen sodium alone (47%; P = .0035), and versus placebo (38%; P = .08). The incidences of the associated symptoms of migraine were significantly lower at 2 hours following sumatriptan 50 mg plus naproxen sodium 500 mg treatment versus placebo ( P < .001). The frequencies and types of adverse events reported did not differ between treatment groups, with dizziness and somnolence being the most common. Conclusions.—This is among the first prospective studies to demonstrate that multimechanism acute therapy for migraine, combining a triptan and an analgesic, is well tolerated and offers improved clinical benefits over monotherapy with these selected standard antimigraine treatments. Specifically, sumatriptan 50 mg (encapsulated) and naproxen sodium 500 mg resulted in significantly superior pain relief as compared to monotherapy with either sumatriptan 50 mg (encapsulated) or naproxen sodium 500 mg for the acute treatment of migraine. Because encapsulation of the sumatriptan for blinding purposes may have altered its pharmacokinetic profile and thereby decreased the efficacy responses, additional studies are warranted that do not involve encapsulation of the active treatments and assess the true onset of action of multimechanism therapy in migraine. This study did show that the combination of sumatriptan and naproxen sodium was well tolerated and that there was no significant increase in the incidence of adverse events compared to monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Orofacial pain management: current perspectives
Romero-Reyes, M., & Uyanik, J. M. (2014) · Journal of Pain Research · doi:10.2147/jpr.s37593 · Cited by 303
Sumatriptan-Naproxen for Acute Treatment of Migraine: A Randomized Trial
Brandes, J. L., Kudrow, D., Stark, S. R., O’Carroll, C. P., Adelman, J. U., O’Donnell, F. J., Alexander, W. J., Spruill, S. E., Barrett, P. S., & Lener, S. E. (2007) · JAMA · doi:10.1001/jama.297.13.1443 · Cited by 276
Self-citationMoore, R. A., Derry, C. J., Derry, S., Straube, S., & McQuay, H. J. (2012) · European Journal of Pain · doi:10.1016/j.ejpain.2011.08.009 · Cited by 63
A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches
Peck, J., Urits, I., Zeien, J., Hoebee, S., Mousa, M., Alattar, H., Kaye, A. D., & Viswanath, O. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-00852-0 · Cited by 37
Metadata
- Authors
- Smith, T. R., Sunshine, A., Stark, S. R., Littlefield, D. E., Spruill, S. E., & Alexander, W. J.
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2005-08-16
- Volume
- 45
- Issue
- 8
- Pages
- 983-991
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2134962635
- Cited by
- 166
- References
- 0
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine. https://app.cochat.ai/papers/10.1111/j.1526-4610.2005.05178.x
- The paper
- Smith, T. R., Sunshine, A., Stark, S. R., Littlefield, D. E., Spruill, S. E., & Alexander, W. J. (2005). Sumatriptan and Naproxen Sodium for the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2005.05178.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.